Recent Evidence of Shifting Cancer Drug Development Pathways

Changes in Numbers of Randomized vs. Non-Randomized Clinical Trials: Recent Evidence of Shifting Cancer Drug Development Pathways

Randomized clinical trials are most often used to demonstrate efficacy of novel anti-cancer drugs. Recently, several oncology drugs have shown efficacy in early phase studies and received regulatory approval based on data from non-randomized studies. Our recent research published in the Journal of Clinical Trials sought to determine if changes in numbers of non-randomized (NRCT) vs. randomized (RCT) oncology trials in recent years suggested a shift in oncology drug development pathways related to a better understanding of cancer biology and a more flexible regulatory drug approval process.

 

Click here to download the journal article

Contact Us
Call Our Team 

Phone: +1 919 876 9300
Fax: +1 919 876 9360
Toll-Free: +1 866 462 7373

Corporate Headquarters

3201 Beechleaf Court
Suite 600
Raleigh, NC 27604-1547